IDT Biologika
IDT Biologika is an international leader in the contract development and manufacture of Viral Vaccines, Viral Vectors for Gene and Immune Therapeutics, Oncolytic Viruses, Virus-Like Particles, and other biologics. We are a full-service biologics CDMO providing end-to-end services and have supported clients in developing some of the leading human vaccines in use today against infectious diseases and viruses around the world.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
In response to rapid growth and demand in new modalities like gene therapy and immunotherapeutics, we also offer development and manufacturing of Viral Vectors and provide liquid and lyophilized fill-finish of other biologics such as monoclonal antibodies and recombinant proteins used as biotherapeutics. IDT Biologika has spent a century committed to the protection and improvement of human health worldwide, and our experienced international team is dedicated to partnering with clients to continue this effort into the future.
In 2021, IDT Biologika reached the landmark of 100 years working in the development and manufacture of vaccines that protect humans all around the world. We continually put this unparalleled experience to work for our customers and in the last two decades have been involved in development and production of vaccines against infectious diseases such as COVID-19, influenza, smallpox, AIDS, malaria, Ebola, Chikungunya, Lassa fever, and Dengue fever. IDT Biologika has also worked on the production of vaccines against certain cancers. Our vision is to remain at the forefront of vaccines that offer critical protection to patient populations worldwide and continue to pioneer vital treatments for the next century.
IDT Biologika is a global biologics manufacturing organization, and we meet the needs of multinational customers and pharma companies around the world with manufacturing capabilities in both Europe and North America. We are headquartered in Dessau-Rosslau, Germany, with a second site in Magdeburg, Germany. Our North American facility is close to Washington, D.C., in Rockville, Maryland. These locations support our fully integrated services and are cGMP and BSL-3 or BSL-2 -compliant, with approvals from the FDA, EMA, and ANVISA.
At IDT Biologika, we recognize how critical vaccines and novel therapeutics are to protecting and improving quality of life for patients around the world. This is the inspiration for investment and growth of our business. We continue to expand our operations in Europe and North America, focused on delivering the highest quality end-to-end services with the ability to scale projects from development and preclinical volumes through to large-scale production and commercial packaging and supply. As part of a €114 million expansion, we are creating additional capacity in drug substance manufacturing, aseptic fill-finish, and visual inspection, which will be online and operational at the end of 2022. Everything we do is underscored by our commitment to quality and operational excellence.
The IDT Difference
The steady growth in biologics in the last few decades is set to continue, and new modalities will take the need for expertise and capacity further. Within biologics, experience with live viruses and the capability and infrastructure to manufacture to relevant biosafety levels is a challenging niche, and IDT Biologika is a CDMO with significant experience and is thus a leader in this area.
Our state-of-the-art facilities serve as a critical translational bridge from process development through clinical to commercial BSL-2 and BSL-3 manufacturing. We have shown over many years that we can address significant challenges and meet the program needs of vaccine and biopharmaceutical companies. This is highlighted by our track record over the last two decades that includes involvement with many of the leading vaccines successfully developed to combat disease. We also have the experience, flexibility, and equipment to support most platform technologies.
100
YEARS OF EXPERIENCE IN VACCINES
50+
CLINICAL TRIAL MATERIALS PRODUCED
420
CLINICAL TRIAL BATCHES IN THE LAST 8 YEARS
30
YEARS OF COMMERCIAL FILLINGS
Our team has exceptional depth and breadth of experience in third-party viral and biologics manufacturing procedures. We work with our customers to handle difficult and complex projects, enabling the transition from early concept through clinical trials to commercial manufacture. IDT Biologika cross-trains process development and GMP manufacturing teams so that there is a strong integration of knowledge and success in scaling up processes. Development staff will work to ensure that there is a seamless transition into GMP manufacturing conditions, and there is an incredible depth of knowledge of the breadth of technologies we offer and what they can do for customers’ processes, across IDT Biologika’s end-to-end operational capabilities.
IDT Biologika intuitively understands the value of technological flexibility and exploring different approaches to solving difficult problems. With years of experience solving a wide range of challenges with live virus processes, and evaluating and using different technologies, we can bring an unparalleled level of innovation to our clients’ projects. Innovation predominantly comes from our people drawing on their great experience and know-how, but the depth and breadth of that knowledge also comes from the diversity of manufacturing platforms and technologies we employ and have had experience using over many years.